Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care.
Naveed Saleh, MD, MS
Prognostic signature associated with AML relapse risk potential harbors gene subsets that apply to only certain patient subgroups.
In this study, FLT3-IRAK1/4 inhibitor (NCGC1481) removed adaptively resistant FLT3-mutant AML cells.
Age disparities in oncology trials are continuing, despite opposition to this issue.
Video-assisted thoracic surgery (VATS) results in fewer in-hospital complications and a shorter length of stay compared with open surgery in patients with early-stage lung cancer.
In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.
Data presented at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer suggested tumor mutational burden may not be associated with the efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy.
Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.
In a phase I trial, researchers demonstrated that KRAS inhibitor AMG 510 demonstrated safety and antitumor activity in advanced NSCLC patients.
Researchers focused on a subset of patients with high tumor mutational burden using a 20-mutation-per-megabase threshold and found significant improvement in progression-free survival and overall survival.